A Phase 2a Trial of Brepocitinib for Cicatricial Alopecia
October 2024
in “
Journal of the American Academy of Dermatology
”
Studysummary In this study, brepocitinib was found to significantly reduce inflammatory biomarker CCL5 expression and improve clinical severity by week 24, while maintaining a favorable safety profile.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on jaad.org →